Does BPC-157 actually work?

Every medical treatment that exists today — aspirin, penicillin, the antibiotic you got last year — started in a lab, moved to animals, and then went through increasingly large human trials before earning regulatory approval. That journey exists because things that work in animals often fail in humans, and safety surprises appear at scale that never showed up in small experiments.

Here's where BPC-157 stands right now: it has a large and reasonably consistent body of animal research, mostly from one research group at the University of Zagreb 1 2, and exactly three published human studies — with a combined total of 30 participants across all three 5 6. There are no large randomized controlled trials in humans. There is no regulatory approval anywhere in the world for any medical use. The FDA actually placed BPC-157 in a category of compounds with "significant safety concerns" in 2023 9, which means it legally cannot be compounded or sold by pharmacies in the United States for patient use.

Animal research is how all medical inquiry starts — aspirin, penicillin, and every drug you've taken went through this stage. But fewer than 1 in 10 animal-tested compounds ever make it through to regulatory approval for humans. That's not a reason to dismiss animal results. It's a reason to treat them as a promising start that needs confirmation, not a finished proof.

One more thing worth knowing before we dive in: almost all of the animal research on BPC-157 comes from a single Croatian research group, and every single study they've published has found positive results. In any field, a pattern like that — one group, zero negative results, across decades — is worth noting as a reason to want independent confirmation. Two independent systematic reviews published in 2025 7 8 both flagged this as a significant limitation of the existing evidence.